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Hypoxic ischaemic encephalopathy (HIE) remains a leading cause of neonatal 
mortality and neurodisability. We aimed to determine the incidence of HIE and 
management patterns against national guidelines.  
Design 
Retrospective cohort study using the National Neonatal Research Database 
Setting  
Neonatal units in England and Wales 
Patients  
Infants 34 to 42 weeks gestational age (GA) with a recorded diagnosis of HIE 
Main Outcomes 
Incidence of HIE, mortality and treatment with therapeutic hypothermia (TH). 
Temporal changes were compared across two epochs (2011-13 and 2014-16). 
Results 
Among 407462 infants admitted for neonatal care, 12195 were diagnosed with HIE. 
8166 infants 36 weeks GA had moderate/severe HIE, 62.1% (n=5069) underwent 
TH and mortality was 9.3% (n=762). Of infants with mild HIE (n=3394), 30.3% 
(n=1027) underwent TH and six died.  In late preterm infants (34-35 weeks GA) with 
HIE (n=635, 5.2%), 33.1% (n=210) received TH and 13.1% (n=83) died. 
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Between epochs (2011-13 vs 2014-16), mortality decreased for infants 36 weeks 
GA with moderate/severe HIE (17.5% vs 12.3%, OR 0.69; 95% CI 0.59-0.81, 
p<0.001). Treatment with TH increased significantly between epochs in infants with 
mild HIE (24.9% vs 35.8%, p<0.001) and those born late preterm (34.3% vs 46.6%, 
p=0.002). 
Conclusions  
Mortality of infants 36 weeks GA with moderate/severe HIE has reduced over time, 
although many infants diagnosed moderate/severe HIE do not undergo TH. 
Increasingly, mild HIE and late preterm infants with HIE are undergoing TH, where 
the evidence base is lacking, highlighting the need for prospective studies to 









Hypoxic ischaemic encephalopathy (HIE) is the leading cause of mortality and 
neurodisability in near-term and term babies. 1 2 Therapeutic hypothermia (TH) is an 
effective, safe treatment for infants 36 weeks gestational age (GA) with 
moderate/severe HIE improving survival and major neurodisability. 1 3 Following the 
TOBY cooling trial 4 and National Institute for Health and Care Excellence guidance 
in 2010, 5 TH is now the standard of care for infants ≥36 weeks GA with 
moderate/severe HIE in the England and Wales. However, recent data on the 
current management and outcomes of infants with HIE in the TH era are lacking. The 
ambitious UK government target of halving brain injury occurring at or soon after 
birth by 2025 requires an understanding of the current incidence and management of 
HIE, allowing healthcare providers to target areas most likely to achieve these 
goals.6 
There are increasing concerns that infants with mild HIE or those more preterm are 
also undergoing TH without evidence of benefit. 7-11 A recent UK survey highlighted 
75% of cooling centres offered TH to infants with mild HIE. 9 Although infants with 
mild HIE have an increased risk of mortality and adverse neurological outcomes, 
there is insufficient evidence to establish any significant benefits or harm with the 
use of TH in these infants. 7 8 For the preterm population, Azzopardi reported 3% 
(n=38) of UK TOBY cooling registrants were 34 or 35 weeks GA with a higher 
mortality rate (30%) compared to more mature infants (20%). 12 Rao et al also found 
preterm infants that received TH had a higher rate of mortality and white matter 
injury compared to term infants that received TH. 10 These studies were limited by 
small numbers. 
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The primary aim of this study was to establish the incidence of HIE in the TH era.  
Secondary aims were to evaluate mortality and changes to TH management.  
METHODS 
Study Population 
The National Neonatal Research Database (NNRD) holds prospectively recorded 
daily clinical data from every infant admitted to UK neonatal units along with 
outcomes. The NNRD contains an approved clinical database (the National Neonatal 
Data Set), within the NHS Data Dictionary national electronic dataset, 13 and 
provides newborn brain injury data in the UK. 2 In 2011, approximately 90% of 
English neonatal units contributed to the NNRD and no units from Wales. From 2012 
onwards, all units contributed to the database. Data are screened for errors and 
amended prior to entry into the database.  
Data from the Office of National Statistics (ONS) were used as denominator data 
(excluding Scotland and Northern Ireland) to calculate national incidence rates of 
HIE, using live birth by GA for each year of the study period. 14  
Data Collection 
Data were extracted on all infants 34 to 42 weeks GA, who were admitted to 
neonatal units in England and Wales from 2011 to 2016. Infants with HIE were 
identified using the “Principle Diagnosis at Discharge” and “HIE score” data fields, as 
diagnosed and inputted by the clinical teams in each centre (Supplementary Table 
1), and allocated the most severe HIE grade issued during their admission. Infants 
managed with any TH were identified using the “Principle Procedures During Stay” 
or “Principle Diagnosis at Discharge” or “Therapeutic Hypothermia” data fields. 
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Infants who did not have a diagnosis of HIE but received TH were not categorised as 
HIE. 
Infants greater than 5500 grams (erroneous data) or missing key episode data items 
(gestational age, principle diagnosis, place of birth or mortality data) were excluded 
from the study.  
Outcome 
The primary aim was the incidence of HIE by live births for England and Wales in the 
TH era.  The secondary aims were to evaluate the management of these infants, 
mortality and describe any temporal changes.  
Statistical Analysis 
Extrapolation methods based on actual admission numbers and number of cases 
from 2012 to 2016 when all units contributed to the database were used to estimate 
the incidence of HIE for 2011 as previously described. 2   
The population incidence rate of HIE per 1000 livebirths was calculated using NNRD 
data to identify cases and ONS data for live birth rates per year by GA as the 
denominator. The study population was divided into two equal epochs (2011 to 2013 
and 2014 to 2016) to evaluate any changes over time.  Infants with moderate/severe 
HIE who died without undergoing TH were considered with babies that received TH 
for analysis as these are likely to represent infants who met cooling criteria but were 
too sick to undergo treatment or care was re-orientated; data for babies that died 
without undergoing TH are also presented. 
For subgroup analyses, infants were further divided into late preterm (34 to 35 weeks 
GA) and mild (Grade 1) HIE subgroups. Associations between demographic, clinical 
variables and death were assessed using chi-squared tests for categorical data and 
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Mann U Whitney for non-normally distributed continuous data. Comparison of 
subgroup characteristics were analysed with univariate analysis and presented as 
unadjusted odds ratio with 95% confidence intervals. All statistical analyses were 
performed using Stata SE (StataCorp, Version 15). 
RESULTS 
A total of 407462 infants were admitted for neonatal care during the study period. Of 
these, 12195 infants had a recorded diagnosis of HIE giving an incidence of 2.96 per 
1000 livebirths and accounting for 3% of neonatal unit admissions ≥34 weeks GA 
(Supplementary Figure 1). Mortality for all infants with recorded HIE was 7.0% 
(n=851).  
The incidence of moderate/severe HIE in infants 36 weeks GA was 2.03 per 1000 
(n=8166); 1.26 per 1000 (n=5069) were treated with TH (n=4949) or died without TH 
treatment (n=120) (Table 1, Supplementary Table 2). The incidence of 
moderate/severe HIE in infants ≥36 weeks GA remained similar between epochs 
(Table 1) but TH treatment significantly increased between epochs (54.6% vs 66.6%, 
p<0.001). 
The characteristics of infants 36 weeks GA with moderate/severe HIE, who did or 
did not undergo TH, were compared (Table 2). Overall, 62.1% (n=5069) of infants 
36 weeks GA with moderate/severe HIE were cooled or died without TH. These 
infants were significantly more likely to have a background of acute intrapartum 
events, need for significant resuscitation, lower Apgar scores and lower cord venous 
pH compared to non-cooled infants. Mortality of infants 36 weeks GA with 
moderate/severe HIE was 9.3% (n=762) and decreased over time between epochs 
(10.0% vs 8.7%, OR 0.85 (95% CI 0.74-0.99), p=0.04). For those undergoing TH 
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(excluding infants who died prior to cooling), there was a significant reduction in 
mortality between 2011-13 (n = 336, 15.1%) and 2014-16 (n = 297, 10.9%, OR 0.67 
(95% CI 0.58-0.81), p<0.001). This pattern remained evident after inclusion of infants 
who died prior to cooling, mortality in epoch 1: 17.5% (n = 402); and in epoch 2: 
12.3% (n = 355); OR 0.69 (95% CI 0.59-0.81, p<0.001). Overall, infants born 
between 2014-16 had a higher rate of early infection and significant resuscitation 
(Supplementary Table 3). 
Infants  36 weeks with mild HIE 
There were 3394 infants 36 weeks GA diagnosed with mild HIE (0.84 per 1000 live 
births), similar between 2011-13 (n=1712) and 2014-16 (n=1682, p=0.57). Mortality 
was low in this population with six deaths overall and no difference over time, 
although infants admitted in 2014-16 had a higher rate of early infection and 
significant resuscitation (Supplementary Table 4). In total, 1027 (30.3%) were 
managed with TH, 338 (10.0%) were transported within the first 48 hours from non-
tertiary units into a cooling centre. The proportion of infants treated with TH 
significantly increased over time between 2011-13 (n=426, 24.9%) and 2014-16 
(n=603, 35.8%, p<0.001).  
The characteristics of infants 36 weeks GA with mild HIE, who did or did not 
undergo TH, were compared (Table 3). Those who received TH (including the 6 
infants who died without TH treatment) had a lower birthweight, required more 
resuscitation, lower Apgar scores and lower cord venous pH. Infants with 
moderate/severe HIE were significantly more likely to have acute intrapartum events, 
require significant resuscitation and had lower Apgar scores compared to infants with 
mild HIE (Supplementary Table 5). 
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Late preterm infants (34 to 35 weeks) 
In total, 635 late preterm infants (6.27 per 1000) were diagnosed with any grade HIE 
(Supplementary Table 6); this remained stable through epoch 1 and 2 with 6.00 per 
1000 vs 6.55 per 1000 respectively (p=0.27). Of these 81.5% (n=518) had 
moderate/severe HIE. Late preterm infants treated with TH were significantly more 
likely to have acute intrapartum events, require significant resuscitation, lower Apgar 
scores and lower cord venous pH (Table 4). 
Among late preterm infants, 259 (40.8%) were treated with TH (n=210) or died 
without TH (n=49). This significantly increased between epoch 1 (n=103, 34.3%) and 
2 (n=156, 46.6%, p=0.002), although mortality remained unchanged (n=36 (12.0%) 
vs n=47 (14.0%), p=0.51). The rate of moderate/severe HIE and the associated 
mortality were greatest in the late preterm population compared to those 36 weeks 
GA (Figure 1 and Supplementary Table 6, P<0.001). Characteristics between 
epochs were similar (Supplementary Table 7). Overall, mortality in infants with 
moderate/severe HIE in the late preterm population was 16.0% (n=83) compared to 
those ≥36 weeks GA at 9.3% (n=762, p=0.005).
DISCUSSION 
This large national population-based study has shown the incidence of recorded 
moderate/severe HIE in infants 36 weeks GA remains similar over time but there 
has been a reduction in mortality. Based on national guidance for HIE, only 62.1% of 
eligible infants received TH. Furthermore, we have shown for the first time the 
increasing number of infants with mild HIE and those born late preterm undergoing 
TH, without sufficient evidence to support this approach . During the most recent 
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epoch, TH was administered to 36% of infants with mild HIE and 47% of late preterm 
infants with HIE. These findings are important particularly for late preterm infants 
where the mortality associated with moderate/severe HIE increases with decreasing 
gestation.   
Following publication of the TOBY trial 4 and national guidance for TH, 5 treatment 
with TH for moderate/severe HIE in infants 36 weeks GA has increased in England 
and Wales, with a reduction in mortality. Mortality for infants undergoing TH has 
decreased by more than half since the TOBY study from 23.9% 4 to 15.1% during 
2011-13 and 10.9% in 2014-16. These findings could reflect changes in practice with 
earlier recognition and treatment, mild cases being diagnosed as moderate and 
undergoing TH, as well as improving intensive care management. In our study, 
37.9% of infants with recorded moderate/severe HIE did not receive TH. These 
infants may include those who were too sick to cool or in whom HIE was diagnosed 
outside the therapeutic cooling window. The clinical decisions for not cooling an 
eligible infant are not recorded within this database. However, the grading of HIE can 
be subjective leading to some clinicians opting not to treat borderline infants, 
whereas others may have graded these infants as moderate HIE. Likewise, infants 
may have been incorrectly misclassified as HIE or misdiagnosed as mild and 
therefore not cooled. Another potential explanation is that TH use was recorded 
inaccurately or was unrecorded despite being administered; however, TH data is 
used to reimburse individual hospitals so this data item is usually well recorded. Our 
findings do, however, potentially suggest a large proportion of eligible infants do not 
receive TH.  
The number of infants with mild HIE undergoing TH has increased over time and 
their mortality rate is very low. Previous studies of infants with mild HIE 
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demonstrated an increased risk of mortality and adverse neurological outcome. 15-17 
However, TH in these infants has not been shown to reduce death or neurodisability, 
7 8 although one study reported less brain injury on MRI scans.18 Management of 
these infants with TH in the absence of robust evidence risks exposing them to 
unnecessary treatment with its associated morbidity, such as pain and respiratory 
support. 19 20 In the UK, TH is mainly undertaken in tertiary centres increasing the 
pressure on cot capacity and specialist neonatal transportation services 21 with the 
need to transfer more infants. Current, on-going prospective studies (TIME 22 and 
COMET 23) may provide much needed evidence to establish the benefit and safety of 
TH use for mild HIE. 
To our knowledge, this is the largest study to date of late preterm infants with HIE 
including those treated with TH. Our study has shown preterm infants have a higher 
incidence rate of moderate/severe HIE diagnosed compared to term infants. The 
TOBY study demonstrated TH was a safe and effective treatment in infants 36 
weeks GA, 4 yet TH is increasingly been used in late preterm infants. Other large 
randomised controlled trials of TH for HIE included 35 week GA infants but did not 
separately report their outcomes. 19 24 25 The pathophysiology of brain injury in late 
preterm infants is likely to be different to those at term,  Rao 10 reported a higher 
incidence of white matter injury and mortality due to the severity of the 
encephalopathy in late preterm infants. Our study also demonstrated late preterm 
infants with moderate/severe HIE were four times more likely to die than infants 36 
week GA (0.80/1000 vs 0.19/1000 live births), highlighting the need for a well-
designed prospective randomised controlled studies to evaluate the safety and 
efficacy in this subgroup. 
Strengths and limitations 
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This study’s main strength is the use of national dataset from a reliable database of 
prospective, routinely recorded data.26 This has allowed analysis with a large sample 
size and provide an estimate of the incidence of HIE within a national healthcare 
service. To our knowledge, this study has analysed the largest group of late preterm 
infants with HIE to date compared to previous studies. 10-12 27 28 Because only 90% of 
neonatal units contributed to the NNRD in 2011 we calculated a lower and upper 
estimate of missing data using actual data from admission and HIE rate from 2012-
2016. 2  
A further strength is the analysis of data after the introduction of a national guideline 
providing diagnostic criteria for treatment, 5 although we acknowledge clinical 
evaluation and grading of HIE are subjective and may lead to variation  with 
diagnosis. Furthermore, the database does not hold the individual components of the 
scoring system, so we were limited by the diagnostic coding of the clinical team 
caring for the infant. To address the ambition to minimise newborn brain injury in the 
UK, 6 it would be useful to standardise recorded data with diagnostic criteria and 
outcomes, allowing more robust national rates and comparisons between centres. 
Inclusion of additional data fields based on established severity scoring systems  
(including modified Sarnat score and aEEG as specified in UK guidance29) could 
help standardisation and accuracy of data entry.  
The main limitation of studies using large databases are errors or imprecision in data 
entry. This is limited through screening the data for erroneous entries, although this 
cannot mitigate completely if the data is incorrect at the point of entry. A further 
limitation is we do not have neuroimaging results or long-term neurodevelopmental 
outcome data as these are not recorded in the database or are often incomplete 
making analysis unreliable. These outcomes would be of significant interest with 
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such a large dataset and is more useful as a measure of brain injury, than 
requirement for TH treatment alone, as many infants will have a normal outcome 
without injury. 
CONCLUSION 
The use of TH for infants with moderate/severe HIE is increasing and is associated 
with a reduction in mortality, although a large proportion of potentially eligible infants 
do not receive treatment. There are also increasing numbers of infants with mild HIE 
and late preterm infants with HIE undergoing TH outside of the current evidence-
base. These data highlight the urgent need for initiatives to improve delivery of 
effective evidence-based practice to all eligible infants and well designed, 
prospective studies to evaluate the safety and efficacy in late preterm infants and 
those with mild HIE. 
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What is already known on this topic –  
• Therapeutic hypothermia is an effective and safe treatment for infants 36 
weeks gestational age with moderate/severe hypoxic-ischaemic 
encephalopathy (HIE), improving survival and reducing severe neurodisability  
• There is insufficient evidence to support the use of therapeutic hypothermia  
for mild HIE or in late preterm infants with HIE 
 
What this study adds –  
• Therapeutic hypothermia use for moderate or severe HIE has increased over 
time, and is associated with a reduction in mortality  
• A large cohort of infants recorded as having moderate/severe HIE do not 
receive treatment with therapeutic hypothermia 
• The use of therapeutic hypothermia for mild HIE and in late preterm infants 
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Table 1: Incidence of hypoxic ischaemic encephalopathy (HIE) for the whole study population, infants 36 weeks gestational age with 
moderate/severe HIE and infants 36 weeks gestational age with moderate/severe HIE treated with therapeutic hypothermia 
 
† Range included to account for 2011 data not available for all hospitals (see methods) 
*denotes signif icant change between epoch 1 and 2, p<0.001 
GA, Gestational age; TH, Therapeutic Hypothermia






































2012 1916 2.71  1267 1.83 723 57.1 741 58.5 
2013 1906 2.81  1213 1.83 806 66.4 823 67.8 
2014 2135 3.17  1422 2.16 937 65.9 951 66.9 
2015 2104 3.11  1396 2.11 928 66.5 953 68.3 
2016 1881 2.77  1276 1.93 861 67.5 879 68.9 
          
Total 12195 2.96  8166 2.03 4949 60.6 5069 62.1 



















Epoch 2 6120 3.01  4094 2.07 2726 66.6* 2783 68.0* 
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Table 2: Comparison of antenatal and delivery characteristics of infants 36 weeks gestational age admitted to neonatal units with 
moderate/severe hypoxic ischaemic encephalopathy (HIE) who received, or died without, therapeutic hypothermia (TH) or did not receive TH 
 













Diabetes mellitus  19 (0.6) 59 (1.2) 0 1.88 (1.12-3.16) 0.02 
Gestational diabetes 110 (3.6) 186 (3.7) 0 1.02 (0.80-1.30) 0.87 
Preeclampsia 167 (5.5) 233 (4.6) 0  0.24 
Risk factors of early infectiona 788 (25.8) 1116 (22.0) 0 0.81 (0.73-0.90) <0.001 
      
Delivery Characteristics      
Gender (male) 1824 (59.7) 2771 (54.7) 3 (<0.01) 0.81 (0.74-0.89) <0.001 
Gestational age (weeks) 40 (38-41) 40 (38-41) 0 0.89 (0.82-0.97) <0.001 
Birth weight (grams) 3379 (2980-3780) 3340 (2950-3760) 0 0.99 (0.98-1.00) 0.06 
> 98th Centile 173 (5.7) 289 (5.7) 0 1.01 (0.83-1.22) 0.94 
Intrapartum eventsb 238 (7.8) 629 (12.4) 0 1.68 (1.43-1.96) <0.001 
Apgar 1 min 3 (2-4) 1 (1-3) 509 (6.2) 0.34 (0.31-0.37) <0.001 
Apgar 5 min 6 (5-8) 4 (2-6) 503 (6.2) 0.21 (0.19-0.23) <0.001 
Significant resuscitationc 730 (23.9) 3070 (60.6) 0 4.89 (4.39-5.44) <0.001 
Venous cord pH 7.18 (7.04-7.28) 7.13 (6.96-7.25) 2396 (29.5) 0.94 (0.93-0.95) <0.001 
* Data are n (%) or median (interquartile range)     
** Categorical data analysed using Chi Squared test; Non-normally distributed continuous data analysed using Mann U Whitney test; 95% CI, 95% Conf idence Interval 
a Maternal pyrexia, chorioamnionitis, prolonged rupture of  membranes, urinary tract infection 
b Cord prolapse, shoulder dystocia, abruption, reduced fetal movements 
c Chest compression, intubation, drugs 
Data items diabetes mellitus, gestational diabetes, preeclampsia, risk factors for sepsis, intrapartum events and signif icant  resuscitation variables are collected using a tick 
box, so not possible to accurately determine missing data f rom absence of  a characteristic 
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Table 3: Comparison of antenatal and delivery characteristics between infants 36 weeks gestational age admitted to neonatal units with mild 
hypoxic-ischaemic encephalopathy (HIE) who received, or died without, therapeutic hypothermia (TH) or did not receive TH 
 












Diabetes mellitus  18 (0.8) 7 (0.7) 0 0.88 (0.37-2.12) 0.78 
Gestational diabetes 81 (3.5) 26 (2.5) 0 0.72 (0.46-1.13) 0.15 
Preeclampsia 96 (4.1) 33 (3.2) 0 0.77 (0.52-1.16) 0.21 
Risk factors of early infectiona 441 (18.9) 211 (20.5) 0 1.11 (0.92-1.33) 0.27 
      
Delivery Characteristics 
Gender (male) 1425 (61.0) 590 (57.5) 1 0.86 (0.74-1.00) 0.05 
Gestational age (weeks) 40(39-41) 40(39-41) 0 0.95 (0.83-1.08) 0.43 
Birth weight (grams) 3410 (3026-3800) 3360 (2965-3740) 0 0.98 (0.97-0.99) 0.005 
> 98th Centile 121 (5.2) 33 (3.2) 0 0.61 (0.41-0.90) 0.01 
Intrapartum eventsb 170 (7.3) 89 (8.7) 0 1.21 (0.92-1.57) 0.17 
Apgar 1 min 4(2-6) 3(1-5) 152 (4.7) 0.47 (0.41-0.54) <0.001 
Apgar 5 min 7(5-8) 5 (4-7) 141 (4.3) 0.34 (0.30-0.40) <0.001 
Significant resuscitationc 431 (18.4) 433 (42.1) 0 3.21 (2.71-3.80) <0.001 
Venous cord pH 7.16(7.04-7.27) 7.14 (6.99-7.25) 892 (27.3) 0.97 (0.96-0.98) <0.001 
* Data are n (%) or median (interquartile range)     
** Categorical data analysed using Chi Squared test; Non-normally distributed continuous data analysed using Mann U Whitney test ; 95% CI, 95% Conf idence Interval; 
a Maternal pyrexia, Chorioamnionitis, prolonged rupture of  membranes, urinary tract infection 
b Cord prolapse, shoulder dystocia, abruption, reduced fetal movements  
c Chest compression, intubation, drugs 
Data items diabetes mellitus, gestational diabetes, p reeclampsia, risk factors for sepsis, intrapartum events and signif icant resuscitation variables are collected using a tick 
box, so not possible to accurately determine missing data f rom absence of  a characteristic  
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Table 4:  Comparison of antenatal and delivery characteristics of infants 34-35 weeks gestational age admitted to neonatal units with hypoxic 
ischaemic encephalopathy who received, or died without, therapeutic hypothermia (TH) or did not receive TH  
     












Diabetes mellitus  10 (2.7) 11 (4.2) 0 1.58 (0.66-3.78) 0.30 
Gestational diabetes 21 (5.7) 20 (7.7) 0 1.37 (0.73-2.59) 0.32 
Pre-eclampsia 51 (13.9) 25 (9.7) 0 0.66 (0.40-1.10) 0.11 
Risk factors of early infectiona 98 (26.8) 64 (24.7) 0 0.90 (0.62-1.29) 0.56 
 
Delivery Characteristics 
Gender (male) 214 (58.5) 152 (58.7) 1 1.00 (0.73-1.39) 0.99 
Gestational age (weeks) 35 (34-35) 35 (34-35) 0 1.92 (1.38-2.69) 0.01 
Birth weight (grams) 2250 (2000-2540) 2344 (2080-2640) 0 1.05 (1.01-1.08) <0.01 
> 98th Centile 20 (5.5) 18 (7.0) 0 1.29 (0.67-2.50) 0.44 
Intrapartum eventsb 50 (13.7) 58 (22.4) 0 1.82 (1.19-2.77) <0.001 
Apgar 1 min 3 (1-5) 1 (0-3) 30 (4.8) 0.23 (0.17-0.32) <0.001 
Apgar 5 min 6 (4-8) 3 (1-5) 34 (5.4) 0.18 (0.13-0.24) <0.001 
Significant resuscitationc 113 (30.9) 175 (67.6) 0 4.66 (3.23-6.73) <0.001 
Venous cord pH 7.16 (6.95-7.28) 7.06 (6.85-7.25) 226 (36.2) 0.93 (0.90-0.97) 0.003 
95% CI, 95% Conf idence Interval; GA, Gestational age;   
* Data are n (%) or median (interquartile range)  
** Categorical data analysed using Chi Squared test; Non-normally distributed continuous data analysed using Mann U Whitney test    
a Maternal pyrexia, chorioamnionitis, prolonged rupture of  membranes, urinary tract infection 
b Cord prolapse, shoulder dystocia, abruption, reduced fetal movements 
c Chest compression, intubation, drugs 
Data items diabetes mellitus, gestational diabetes, preeclampsia, risk factors for sepsis, intrapartum events and signif icant  resuscitation variables are collected using a tick 




Figure 1. Rate of moderate/severe hypoxic ischaemic encephalopathy treated with 
therapeutic hypothermia and mortality within the study population per 1000 livebirths 
at each gestational week 
 
 
M/S, Moderate/Severe; HIE, Hypoxic ischaemic encephalopathy; TH, Therapeutic Hypothermia 
* Data includes infants with M/S HIE, but were not cooled
 
